

Pulmonary/Allergy Drugs Advisory Committee Meeting
Jan 17, 2002
Holiday Inn Gaithersburg

Flovent Diskus (NDA# 20-833/S-004) and Advair Diskus (NDA# 21-077/S-003) as long-term maintenance therapy in patients with Chronic Obstructive Pulmonary Disease (COPD).

8:00	Welcome Conflict of Interest Statement	Mark S. Dykewicz, M.D. Kimberly Topper
8:15	Welcome and Topic Introduction	Robert Meyer, M.D.
8:30	GlaxoSmithKline Presentations Introduction Scientific & Clinical Rationale Clinician's Perspective Clinical Efficacy & Safety Conclusions and Q&A	Dr. David Wheadon Dr. Malcolm Johnson Dr. James Donohue Dr. Tushar Shah Dr. David Wheadon
10:15	Break	
10:30	FDA Presentations Flovent Diskus for COPD Advair Diskus for COPD Summary and Issues for PADAC	Dr. Charles Lee Dr. Lydia Gilbert-McClain Dr. Mary Purucker
12:00	Lunch	
1:00	Open Public Hearing Sol Epstein, MD, FRCP, FACP	
2:00	Discussion	
3:00	Break	
3:15	Questions	
5:00	Adjourn	